Glutathione depletion overcomes resistance to arsenic trioxide in arsenic-resistant cell lines

Leukemia

Volumn 17, Issue 5, 2003, Pages 931-940

  Davison, K ^a   Cote S ^a   Mader, S ^b   Miller Jr , W H ^a  

^a MCGILL UNIVERSITY   (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Acute promyelocytic leukemia; Arsenic resistance; Arsenic trioxide; Glutathione; Reactive oxygen species

Indexed keywords

ARSENIC TRIOXIDE; BUTHIONINE SULFOXIMINE; GLUTATHIONE; HYBRID PROTEIN; LIPOCORTIN 5; ONCOPROTEIN; RETINOIC ACID RECEPTOR ALPHA;

APOPTOSIS; ARTICLE; CELL GROWTH; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG RESISTANCE; DRUG SENSITIVITY; GROWTH INHIBITION; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; MOLECULAR CLONING; NICK END LABELING; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN DEPLETION; PROTEIN EXPRESSION; SENSITIVITY ANALYSIS;

EID: 0037851760     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2402876     Document Type: Article

References (48)

1. Chen GQ, Shi XG, Tang W, Xiong SM, Zhu J, Cai X et al. Use of arsenic trioxide in the treatment of acute promyelocytic leukemia (APL): I. arsenic trioxide exerts dose-dependent dual effects on APL cells. Blood 1997; 89: 3345-3353.
2. Shen ZX, Chen GQ Ni JH, Li XS, Xiong SM, Qiu QY et al. Use of arsenic trioxide in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood 1997; 89: 3354-3360.
3. Soignet SL, Maslak P, Wang Z, Jhanwar S, Calleja E, Dardashti LJ et al. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl J Med 1998; 339: 1341-1348.
4. Miller Jr WH, Warrell Jr RP, Frankel SR, Jakubowski A, Gabrilove JL, Muindi J et al. Novel retinoic acid receptor-α transcripts in acute promyelocytic leukemia responsive to all-trans-retinoic acid. J Natl Cancer Inst 1990; 32: 1932-1933.
5. Kakizuka A, Miller Jr WH, Umesono K, Warrell Jr RP, Frankel SR, Murty VV et al. Chromosomal translocation t(15;17) in human acute promyelocytic leukemia fuses RAR alpha with a novel putative transcription factor, PML. Cell 1991; 66: 663-674.
6. Rosenauer A, Raelson JV, Nervi C, Eydoux P, DeBlasio A, Miller Jr WH. Alterations in expression, binding to ligand and DNA, and transcriptional activity of rearranged and wildtype retinoid receptors in retinoid-resistant acute promyelocytic leukemia cell lines. Blood 1996; 88: 2671-2682.
7. de The H, Marchio A, Tiollais P, Dejean A. A novel steroid/thyroid hormone receptor-related gene inappropriately expressed in human hepatocellular carcinoma. Nature 1987; 330: 667-670.
8. Castaigne S, Chomienne C, Daniel MT, Berger R, Fenaux P, Degos L. All-trans retinoic acid as a differentiation therapy for acute promyelocytic leukemia. I. Clinical results. Blood 1990; 76: 1704-1709.
9. Chen ZX, Xue YQ, Zhang R, Tao RF, Xia XM, Li C et al. A clinical and experimental study on all-trans retinoic acid treated acute promyelocytic leukemia patients. Blood 1991; 78: 1413-1419.
10. Raelson JV, Nervi C, Rosenauer A, Benedetti L, Monczak Y, Pearson M et al. The PML/RARα oncoprotein is a direct molecular target of retinoic acid in acute promyelocytic leukemia cells. Blood 1996; 88: 2826-2832.
11. Shao W, Fanelli M, Ferrara FF, Riccioni R, Rosenauer A, Davison K et al. Arsenic trioxide as an inducer of apoptosis and loss of PML-RARα protein in acute promyelocytic leukemia cells. J Natl Cancer Inst 1998; 90: 124-133.
12. Chen G, Zhu J, Shi X, Ni J, Zhong H, Si G et al. In vitro studies on cellular and molecular mechanisms of arsenic trioxide in the treatment of acute promyelocytic leukemia: arsenic trioxide induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RARα/PML proteins. Blood 1996; 88: 1052-1061.
13. Dai J, Weinberg RS, Waxman S, Jing Y. Malignant cells can be sensitized to undergo growth inhibition and apoptosis by arsenic trioxide through modulation of the glutathione redox system. Blood 1999; 93: 268-277.
14. Wang H-F, Lee T-C. Glutathione S-transferase pi facilitates the excretion of arsenic from arsenic-resistant Chinese hamster ovary cells. Biochem Biophys Res Comm 1993; 192: 1093-1099.
15. Chen Z, Mutoh M, Sumizawa T, Furukawa T, Haraguchi M, Tani A et al. Reversal of heavy metal resistance in multidrug-resistant human KB carcinoma cells. Bioch Biophys Res Comm 1997; 236: 586-590.
16. Lo J, Wang H, Tam M, Lee T. Glutathione S-transferase pi in an arsenic-resistant Chinese hamster ovary cell line. Biochem J 1992; 288: 977-981.
17. Ishikawa T, Ali-Osman F. Glutathione-associated cis-diamminedichloroplatinum(II) metabolism and ATP-dependent efflux from leukemia cells. J Biol Chem 1993; 268: 20116-20125.
18. Zaman GJR, Lankelma J, van Tellingen O, Beijnen J, Dekker H, Paulusma C et al. Role of glutathione in the export of compounds from cells by the multidrug-resistance-associated protein. Proc Natl Acad Sci USA 1995; 92: 7690-7694.
19. Chen Z-S, Mutoh M, Sumizawa T, Furukawa T, Haraguchi M, Tani A et al. An active efflux system for heavy metals in cisplatin-resistant human KB carcinoma cells. Exp Cell Res 1998; 240: 312-320.
20. Cole SPC, Sparks KE, Fraser K, Loe DW, Grant CE, Wilson GM et al. Pharmacological characterization of multidrug resistant MRP-transfected human tumor cells. Cancer Res 1994; 54: 5902-5910.
21. Larochette N, Decaudin D, Jacotot E, Brenner C, Marzo I, Susin SA et al. Arsenite induces apoptosis via a direct effect on the mitochondrial permeability transition pore. Exp Cell Research 1999; 249: 413-421.
22. Li YM, Broome JD. Arsenic targets tubulins to induce apoptosis in myeloid leukemia cells. Cancer Res 1999; 59: 776-780.
23. Cavigelli M, Li WW, Lin A, Su B, Yoshioka K, Karin M. The tumor promoter arsenite stimulates AP-1 activity by inhibiting a JNK phosphatase. EMBO 1996; 15: 6269-6279.
24. Hei TK, Liu SX, Waldren C. Mutagenicity of arsenic in mammalian cells: role of reactive oxygen species. Proc Natl Acad Sci USA 1998; 95: 8103-8107.
25. Wang T, Kuo C, Jan K, Huang H. Arsenite induces apoptosis in Chinese hamster ovary cells by generation of reactive oxygen species. J Cell Physiol 1996; 169: 256-268.
26. Chen Y, Lin-Shiau S, Lin J. Involvement of reactive oxygen species and caspase 3 activation in arsenite-induced apoptosis. J Cell Physiol 1998; 177: 324-333.
27. Watson RWG, Redmond HP, Wang JH, Bouchier-Hayes D. Mechanisms involved in sodium arsenite-induced apoptosis of human neutrophils. J Leukocyte Biol 1996; 60: 625-632.
28. Liu SX, Athar M, Lippai I, Waldren C, Hei TK. Induction of oxyradicals by arsenic: implication for mechanism of genotoxicity. Proc Natl Acad Sci 2001; 98: 1643-1648.
29. Wang TS, Shu YS, Liu KY, Huang H. Glutathione peroxidase and catalase modulate the genotoxicity of arsenite. Toxicology 1997; 121: 229-237.
30. Côté S, Zhou D, Bianchini A, Nervi C, Gallagher RE, Miller Jr WH. Altered ligand binding and transcriptional regulation by mutations in the PML/RAR ligand-binding domain arising in retinoic-acid-resistant patients with acute promyelocytic leukemia. Blood 2000; 96: 3200-3208.
31. Ding W, Li Y, Nobile LM, Grills G, Carrera I, Paietta E et al. Leukemic cellular retinoic acid resistance and missense mutations in the PML-RARa fusion gene after relapse of acute promyelocytic leukemia from treatment with all-trans retinoic acid and intensive chemotherapy. Blood 1998; 92: 1172-1183.
32. Shao W, Benedetti L, Lamph WW, Nervi C, Miller Jr WH. A retinoid-resistant acute promyelocytic leukemia subclone expresses a dominant negative PML-RARα mutation. Blood 1997; 89: 4282-4289.
33. Imaizumi M, Suzuki H, Yoshinari M, Sato A, Saito T, Sugawara A et al. Mutations in the E-domain of RARα portion of the PML/RARα chimeric gene may confer clinical resistance to all-trans retinoic acid in acute promyelocytic leukemia. Blood 1998; 92: 374-382.
34. Konig A, Wrazel L, Warrell Jr RP, Rivi R, Pandolfi PP, Jakubowski A et al. Comparitive activity of melarsoprol and arsenic trioxide in chronic B-cell leukemia lines. Blood 1997; 90: 562-570.
35. Wang Z, Rivi R, Delva L, Konig A, Scheinberg DA, Gambacorti-Passerini C et al. Arsenic trioxide and melarsoprol induce programmed cell death in myeloid leukemia cell lines and function in a PML and PML-RARa independent manner. Blood 1998; 92: 1497-1504.
36. Gianni M, Koken MHM, Chelbi-Alix MK, Benoit G, Lanotte M, Chen Z et al. Combined arsenic and retinoic acid treatment enhances differentiation and apoptosis in arsenic-resistant NB4 cells. Blood 1998; 91: 4300-4310.
37. Nason-Burchenal K, Takle G, Pace U, Flynn S, Allopenna J, Martin P et al. Targeting the PML/RARα translocation product triggers apoptosis in promyelocytic leukemia cells. Oncogene 1998; 17: 1759-1768.
38. Wang ZG, Ruggero D, Ronchetti S, Zhong S, Gaboli M, Rivi R et al. PML is essential for multiple apoptotic pathways. Nat Genet 1998; 20: 266-272.
39. Testa U, Grignani F, Samoggia P, Zanetti C, Riccioni R, Lo Coco F et al. The PML/RARα fusion protein inhibits tumor necrosis factor-alpha - induced apoptosis in U937 cells and acute promyelocytic leukemia blasts. J Clin Inv 1998; 101: 2278-2289.
40. Jing Y, Wang L, Xia L, Chen GQ, Chen Z, Miller Jr WH et al. Combined effect of all-trans retinoic acid and arsenic trioxide in acute promyelocytic leukemia cells in vitro and in vivo. Blood 2001; 97: 264-269.
41. Lallemand-Breitenbach V, Guillemin MC, Janin A, Daniel MT, Degos L, Kogan SC et al. Retinoic acid and arsenic synergize to eradicate leukemic cells in a mouse model of acute promyelocytic leukemia. J Exp Med 1999; 189: 1043-1052.
42. Schecter RL, Alaoui-Jamali MA, Woo A, Fahl WE, Batist G. Expression of a rat glutathione-s-transferase complementary DNA in rat mammary carcinoma cells: impact upon alkylator-induced toxicity. Cancer Res 1993; 53: 4900-4906.
43. Batist G, Schecter R, Woo A, Greene D, Lehnert S. Glutathione depletion in human and rat multi-drug resistant breast cancer cell lines. Biochem Pharma 1991; 41: 631-635.
44. Batist G, Schecter RL, Alaoui-Jamali MA. The glutathione system and drug resistance. In: Schilsky RL, Milano GA, Ratain MJ, (eds). Principles of Antineoplastic Drug Development and Pharmacology. New York: Marcel Dekker, Inc., 1996, pp 503-521.
45. Chin K-C, Tanaka S, Darlington G, Pastan I, Gottesman MM. Heat shock and arsenite increase expression of the multidrug resistance (MDR1) gene in human renal carcinoma cells. J Biol Chem 1990; 265: 221-226.
46. Ishikawa T, Bao J-J, Yamane Y, Akimaru K, Frindrich K, Wright CD et al. Coordinated induction of MRP/GS-X pump and gamma-glutamylcysteine synthetase by heavy metals in human leukemia cells. J Biol Chem 1996; 271: 14981-14988.
47. Tew KD. Glutathione-associated enzymes in anticancer drug resistance. Cancer Res 1994; 54: 4313-4320.
48. O'Dwyer PJ, Hamilton TC, LaCreta FP, Gallo JM, Kilpatrick D, Halbherr T et al. Phase I trial of buthionine sulfoximine in combination with melphalan in patients with cancer. J Clin Oncol 1996; 14: 249-256.